Peptide blends: what a multi-peptide vial is, how a blend's Certificate of Analysis works, and how to compare listings

What a blend is, physically#

A single-peptide research vial contains one lyophilized compound and, usually, a small amount of excipient such as mannitol that gives the freeze-dried cake its structure. A blend is made by combining solutions of two or more peptides in a defined proportion, filling the mixture into vials, and lyophilizing the mixture as one cake. Once dried, the components cannot be separated by eye or by weight: the vial contains a single white or off-white solid, and only an analytical method can say what is in it and in what proportion.

That last point is the whole subject of this page. With a single-peptide vial, identity testing answers one question (is this the stated molecule?) and purity testing answers another (how much of the material is that molecule?). With a blend, there are two or more identity questions, two or more quantity questions, and a third question that single vials never raise: is the ratio what the label says?

Reading a blend label#

Blend labels follow a handful of conventions, and they are not interchangeable.

Two vials labelled "10 mg" can be entirely different products: 5 mg plus 5 mg of two peptides, or 9 mg of one and 1 mg of the other. Likewise, two vials with the same ratio and different totals (a "5/5" and a "10/10") are different products at different prices and should be compared per milligram of each component, not per vial. Our earlier note on the "Wolverine stack" nickname walks through that comparison for the most common two-peptide blend.

What a blend Certificate of Analysis has to show#

A Certificate of Analysis (COA) for a single peptide normally reports one HPLC purity figure and one mass-spectrometry identity confirmation. A blend COA that reports a single purity figure is reporting something ambiguous: HPLC separates the components into distinct peaks, so a competent report either shows each peak assigned to its component with its own area, or explains why it cannot. The elements a reviewer should look for are:

1. Identity for every component. Each peptide's expected mass should be confirmed separately, because a mass spectrum of the mixture contains one signal per component. A report that confirms only the largest component has only half-tested the vial.
2. A chromatogram with assigned peaks. The HPLC trace should label which peak belongs to which peptide. Co-eluting peaks (two peptides leaving the column at the same time) are a known complication and should be stated if they occur.
3. Quantity or ratio. The strongest reports give the measured amount of each component, or at least the measured ratio, against the label claim. Many reports in this market do not; if the report gives only purity, regard the label's ratio as unverified.
4. The same lot number as the vial. A blend report is specific to a filling run. A report for a different lot, or one with no lot number, describes a different vial.
5. Method, laboratory and date. As for any COA, the report should name the method, the issuing laboratory and when the analysis was done.

General validation principles for analytical methods, including specificity (the ability to measure the intended analyte in the presence of others, which is exactly the blend problem) are set out in the ICH Q2(R2) guideline adopted by the FDA.^[1] A laboratory working to that standard will have demonstrated that its HPLC method resolves the components of a given blend before reporting on it.

Why blends are harder to document than single peptides#

The practical reasons are worth understanding, because they explain why so many blend listings carry weaker documentation than the single vials beside them.

• Method development. An HPLC method that separates peptide A from its impurities may not separate it from peptide B. Each blend needs its own method, and that costs the vendor time and money that a single-peptide method does not.
• Reference standards. Quantifying each component requires a reference standard for each, run on the same system. A vendor that tests single peptides against one standard needs several for a blend.
• Variable raw material. The components are purchased separately and often from separate sources. If one arrives at a different net peptide content than expected, the finished ratio shifts unless the blend is formulated by measured content rather than by nominal mass.
• Fewer independent reports. Third-party testing services that publish results for single peptides have far less published data on blends, so buyers have fewer outside reference points.

Comparing two blend listings#

A short procedure that takes a few minutes per listing:

1. Write down each component and its stated amount. If a listing gives only a total, note that the ratio is unstated.
2. Divide the price by the amount of each component to get a per-milligram cost per component. Compare like with like.
3. Open the COA. Check that it carries the lot number on the vial you would receive, names every component, and shows a chromatogram with assigned peaks.
4. Check whether quantity or ratio was measured, or only purity.
5. Note the form of each component (free peptide or salt), since salt forms weigh more per unit of peptide and the label mass may refer to either.

Renuvia's own blends are listed on the Blends collection page with their components and totals; each lot's testing status, including which of the items above its report covers, is shown in the COA library and is marked pending until the laboratory issues the report.